According to the Complaint, Inphi Corporation is a fabless provider of high-speed analog and mixed signal semiconductor solutions for the communications and cloud markets.
Recent Security Class Actions
According to the Complaint, Penumbra, Inc. is a global healthcare company that develops, manufactures and sells innovative medical devices for patients suffering from stroke and other vascular and neurovascular diseases. Penumbra was the first company to market aspiration catheters, a specialized catheter designed to remove blood clots from arteries and veins in stroke patients, in a surgical procedure known as a thrombectomy.
According to the Complaint, Decision Diagnostics Corp. purportedly offers, among other products and services, prescription and non-prescription diagnostics and home testing products. From March 2020 to at least June 2020, Defendants claimed that the Company had developed a finger-prick blood test that could detect COVID-19 in less than one minute. Defendants also made various representations regarding the Company’s progress towards achieving U.S. Food and Drug Administration emergency use authorization (“EUA”) for this purported COVID-19 finger-prick blood test.
According to the Complaint, Nielsen Holdings plc is a global measurement and data analytics company providing a view of consumers and markets worldwide.
According to the Complaint, Xilinx, Inc. (“Xilinx” or the “Company”) is a technology company that designs and develops programmable devices and associated technologies. In additional to its programmable platforms, Xilinx also provides design services, customer training, field engineering and technical support.
According to the Complaint, Zagg Inc (“ZAGG” or the “Company”) designs, manufactures, and distributes mobile tech accessories for smartphones, tablets, smartwatches, and other mobile technology in the United States, Europe, and internationally.
According to the Complaint, GTT Communications, Inc. operates a global communications network, providing telecommunications services to large, multinational enterprises, carriers, and governments across five continents.
According to the Complaint, Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States.
According to the Complaint, Slack Technologies, Inc. (“Slack”) operates Slack, a business technology software platform that brings together people, applications, and data, and sells access to its Slack platform under a software-as-a-service model.
According to the Complaint, Tricida, Inc. is a pharmaceutical company that focuses on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease ("CKD"). Tricida has completed a Phase 3, double-blind, placebo-controlled trial of veverimer in patients with CKD and metabolic acidosis.
